Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:12:02 ON 05 NOV 2007

=>
=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:12:14 ON 05 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5
DICTIONARY FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.25	2.46

FILE 'STNGUIDE' ENTERED AT 16:15:05 ON 05 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 2, 2007 (20071102/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.92	4.38

FILE 'REGISTRY' ENTERED AT 16:34:34 ON 05 NOV 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5
DICTIONARY FILE UPDATES: 4 NOV 2007 HIGHEST RN 952404-20-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\11759704.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:35:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3547 TO ITERATE

56.4% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS:         67368 TO    74512
PROJECTED ANSWERS:                1 TO      114

L2             1 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:35:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    70912 TO ITERATE

100.0% PROCESSED    70912 ITERATIONS                                93 ANSWERS
SEARCH TIME: 00.00.01

L3             93 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     176.48

FILE 'CAPLUS' ENTERED AT 16:35:13 ON 05 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 5 Nov 2007  VOL 147 ISS 20
FILE LAST UPDATED: 4 Nov 2007  (20071104/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4             7 L3

=> d abs fbib hitstr 1-7

L4   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
GI
```



I



II

AB Title compds. I [wherein R1, R2 = independently OH, (cyclo)alkoxy or (fluoro)alkoxy; R3, R31 = H or alkyl; R4 = H or alkyl; R5 = R51 = H; R6 = H, halo, alkyl or alkoxy; R7 = (un)substituted NH2; or their salts and the N-oxides, and the salts of the N-oxides thereof] were prepared, such as II, as PDE4 inhibitors. Selected prepared I showed inhibition of PDE4 with pIC50 values of 7.36 - 9.33. Therefore, I and pharmaceutical compns. thereof are useful for treating PDE-mediated disorders, such as respiratory diseases.

AN 2006:945476 CAPLUS
DN 145:335953

TI Preparation of amido-substituted 6-phenylphenanthridines as PDE4 inhibitors

IN Kautz, Ulrich; Schmidt, Beate; Flockerzi, Dieter; Chiesa, Maria Vittoria; Hatzelmann, Armin; Zitt, Christof; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter
PA Altana Pharma AG, Germany

SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006095009	A1	20060914	WO 2006-EP60595	20060309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 2005-101820 A 20050309

OS MARPAT 145:335953
IT 909778-53-6P 909778-57-0P 909778-59-2P
909778-61-6P 909778-63-8P 909778-69-4P

909778-70-7P 909778-71-8P 909778-72-9P
909778-73-0P 909778-74-1P 909778-75-2P
909778-76-3P 909778-77-4P 909778-79-6P
909778-82-1P 909778-83-2P 909778-85-4P
909778-90-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amido-substituted 6-phenylphenanthridines as PDE4 inhibitors)

RN 909778-53-6 CAPLUS
CN Glycine, N-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-57-0 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[1-(methoxymethyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-59-2 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-

phenanthridinyl]-N-(2-methoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-61-6 CAPLUS
CN Benzamide, N-(2,2-diethoxyethyl)-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-63-8 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(3-hydroxypropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-69-4 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-70-7 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-71-8 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-72-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-73-0 CAPLUS
CN Benzeneacetic acid, 3,4-dimethoxy-, 2-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-74-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-75-2 CAPLUS
CN Benzoic acid, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-, 2-[4-(aminosulfonyl)phenyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-76-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 2-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-77-4 CAPLUS
CN 2-Piperazinecarboxylic acid, 1,4-dimethyl-, 2-[4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-79-6 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-82-1 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-83-2 CAPLUS
CN Glycine, N-[4-[(4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-85-4 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 909778-90-1 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [wherein R1, R2 = OH or (cyclo)alkoxy; R3, R31 = H or alkyl; R4 = OH, alkoxy or alkylcarbonyloxy; R5 = H or alkyl; R6 = H, halo, alkyl or alkoxy; R7 = (un)substituted NH2; etc., or their salts and the N-oxides, and the salts of the N-oxides] were prepared as PDE4 inhibitors. For instance, II (R = OH) was synthesized by hydrolysis of its ester II (R = OAc) with Cs2CO3 in methanol. Representative I, including II (R = OH), were found to inhibit PDE4B2 with pIC50 values of 6.42 - 9.02. Therefore, I and pharmaceutical compns. thereof are useful for treating PDE-mediated

disorders, such as respiratory diseases.
AN 2005:1026938 CAPLUS
DN 143:326233
TI Preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases
IN Schmidt, Beate; Kautz, Ulrich
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005087745	A1	20050922	WO 2005-EP51054	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
AU 2005221832	A1	20050922	AU 2005-221832	20050309
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
CA 2558391	A1	20050922	CA 2005-2558391	20050309
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
EP 1725534	A1	20061129	EP 2005-740073	20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
CN 1926113	A	20070307	CN 2005-80006855	20050309
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
BR 2005008481	A	20070731	BR 2005-8481	20050309
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
JP 2007527901	T	20071004	JP 2007-502343	20050309
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309
US 2007185149	A1	20070809	US 2006-591480	20060927
			EP 2004-100990	A 20040310
			EP 2004-106677	A 20041217
			WO 2005-EP51054	W 20050309

NO 2006004415	A	20061010	NO 2006-4415		20060929
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
IN 2006MN01169	A	20070413	IN 2006-MN1169		20061003
			EP 2004-100990	A	20040310
			WO 2005-EP51054	W	20050309

OS MARPAT 143:326233

IT 865306-83-8P 865306-84-9P 865306-86-1P
865306-87-2P 865306-88-3P 865306-90-7P
865306-91-8P 865306-93-0P 865306-95-2P
865306-98-5P 865306-99-6P 865307-00-2P
865307-01-3P 865307-08-0P 865307-09-1P
865307-10-4P 865307-11-5P 865307-13-7P
865307-15-9P 865307-16-0P 865307-33-1P
865307-34-2P 865307-35-3P 865307-37-5P
865307-38-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibitor; preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases)

RN 865306-83-8 CAPLUS

CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-84-9 CAPLUS

CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-4-morpholinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-86-1 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-87-2 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(4-methyl-1-piperazinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-88-3 CAPLUS
CN Benzoic acid, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-, 2-[3-(aminosulfonyl)phenyl]hydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-90-7 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-3-quinolinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-91-8 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(2-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-93-0 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(2,3-dimethylimidazo[1,2-a]pyridin-7-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-95-2 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-cyclopropyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-98-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-99-6 CAPLUS
CN L-Aspartic acid, N-[4-[2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-00-2 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-01-3 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-1,7-naphthyridin-8-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-08-0 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-09-1 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(3-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-10-4 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-11-5 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(2,6-dimethoxy-3-pyridinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-13-7 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclopropyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-15-9 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-16-0 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-33-1 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(3S,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-3-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-34-2 CAPLUS
CN Benzamide, 3-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-35-3 CAPLUS
CN Benzamide, 3-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-37-5 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-38-6 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 865306-47-4P 865306-48-5P 865306-49-6P
865306-50-9P 865306-52-1P 865306-53-2P
865306-57-6P 865306-66-7P 865306-67-8P
865306-68-9P 865306-69-0P 865306-71-4P
865306-73-6P 865306-74-7P 865307-23-9P
865307-24-0P 865307-25-1P 865307-26-2P
865307-27-3P 865307-28-4P 865307-30-8P
865307-31-9P 865307-40-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases)
RN 865306-47-4 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-48-5 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-49-6 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-(4-methyl-1-piperazinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-50-9 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-4-morpholinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-52-1 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-3-quinolinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-53-2 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(2-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-57-6 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-66-7 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-67-8 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(3-pyridinyl)ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-68-9 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]benzoyl]hydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-69-0 CAPLUS
CN Benzamide, N-(2,6-dimethoxy-3-pyridinyl)-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865306-71-4 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 865306-73-6 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 865306-74-7 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-N-[3-(4-morpholinyl)propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 865307-23-9 CAPLUS
CN Benzamide, N-(2,6-dimethoxy-3-pyridinyl)-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 865307-24-0 CAPLUS
CN Benzamide, N-(2,6-dimethoxy-3-pyridinyl)-4-[(2S,4aS,10bS)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-25-1 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 865307-26-2 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(2S,4aS,10bS)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-27-3 CAPLUS
CN Benzamide, N-cyclopropyl-4-[(2R,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-28-4 CAPLUS
CN Benzamide, N-cyclobutyl-4-[(2R,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-30-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-[(2R,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-31-9 CAPLUS
CN Benzamide, N-cyclobutyl-3-[(2R,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865307-40-0 CAPLUS
CN Benzamide, 4-[(3S,4aR,10bR)-3-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = OH, alkoxy, cycloalkoxy, etc.; R2 = OH, cycloalkylmethoxy, cycloalkoxy, etc. or R1 and R2 together form alkylenedioxy group; R3 = H or alkyl; R4 = OR9 and R5 = H or alkyl or R4 = H or alkyl and R5 = OR9; R6 = H or alkyl; R7 = (un)substituted guanidinyl; R8 = H, halo, nitro, etc.; R9 = H, alkyl, alkoxyalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as phosphodiesterase 4 (PDE4) inhibitors. Thus, e.g., II was prepared by coupling of 4-((2RS,4aRS,10bRS)-2-acetoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid with the resp. guanidinyl derivative followed by hydrolysis. The activity of I was evaluated using scintillation proximity assays and it was revealed that selected compds. of the invention displayed -log IC50 values higher than 7.5. I as inhibitor of PDE4 should provide useful in the treatment of respiratory disorders. Pharmaceutical compns. comprising I are disclosed.
AN 2005:902858 CAPLUS
DN 143:248297
TI Preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors
IN Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005077906	A1	20050825	WO 2005-EP50708		20050217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				EP 2004-3592	A	20040218
	AU 2005212857	A1	20050825	AU 2005-212857		20050217
				EP 2004-3592	A	20040218
				WO 2005-EP50708	W	20050217
	CA 2556086	A1	20050825	CA 2005-2556086		20050217
				EP 2004-3592	A	20040218
				WO 2005-EP50708	W	20050217
	EP 1720835	A1	20061115	EP 2005-708038		20050217
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,					

IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

			EP 2004-3592	A	20040218
			WO 2005-EP50708	W	20050217
JP 2007523130	T	20070816	JP 2006-553593		20050217
			EP 2004-3592	A	20040218
			WO 2005-EP50708	W	20050217
US 2007167482	A1	20070719	US 2006-589082		20060905
			EP 2004-3592	A	20040218
			WO 2005-EP50708	W	20050217

OS MARPAT 143:248297

IT 862993-72-4P 862993-73-5P 862993-74-6P
862993-75-7P 862993-76-8P 862993-77-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors)

RN 862993-72-4 CAPLUS

CN Benzamide, N-[(diethylamino)iminomethyl]-4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 862993-73-5 CAPLUS

CN Benzamide, 4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-N-[(hexahydro-1(2H)-azocinyl)iminomethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 862993-74-6 CAPLUS
CN Benzamide, N-[(cyclopropylamino)iminomethyl]-4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 862993-75-7 CAPLUS
CN Benzamide, N-[(4-acetyl-1-piperazinyl)iminomethyl]-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 862993-76-8 CAPLUS
CN Benzamide, N-[(diethylamino)iminomethyl]-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME).

Relative stereochemistry.



RN 862993-77-9 CAPLUS
CN Benzamide, N-[(hexahydro-1(2H)-azocinyl)iminomethyl]-4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 862993-78-0P 862993-79-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors)
RN 862993-78-0 CAPLUS
CN Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[(4-acetyl-1-piperazinyl)iminomethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 862993-79-1 CAPLUS
CN Carbamimidothioic acid, [4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I

AB The title compds. [I; R1, R2 = HO, C1-4 alkoxy, C3-7 cycloalkoxy, C3-7 cycloalkylmethoxy or completely or predominantly fluorine-substituted C1-4 alkoxy; or R1 and R2 together are a C1-2 alkylenedioxy group; R3, R31 = H, C1-4 alkyl; or R3 and R31 together are a C1-4 alkylene group; R4 = H, C1-4 alkyl and R51 = H; or R5 and R51 together represent an addnl. bond; R6 = H, halogen, nitro, C1-4 alkyl, CF3, C1-4 alkoxy; R7 = (un)substituted guanidino, heterocyclylamino, 1-heterocyclyl-1-(imino)methyl, etc.] or salts thereof, as well as N-oxides, enantiomers, E/Z isomers, or tautomers thereof and their salts are prepared These compds. I are useful for producing pharmaceutical compns. for treating respiratory disorders and/or dermatoses. Also disclosed is a method for treating an illness treatable by administration of a PDE4 inhibitor in a patient comprising administering to said patient in need thereof a therapeutically effective amount of a compound of formula I, in particular airway disorders.

N'-[1-[4-[(4aR,10bR)-8,9-Dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-6-yl]phenyl]methanoyl]-N,N-diethylguanidine. Thus, 4.9 g 1,1-diethylguanidinium sulfate was suspended in 120 mL MeCN, treated with 720 mg NaOH in 25 mL MeOH, and stirred at room temperature for 1 h. The solvent was evaporated and the residue was suspended in 200 mL CH2Cl2, treated with 5.2 g Na2CO3 and then dropwise with a solution of 4.2 g 4-[(4aR,10bR)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-6-yl]benzoyl chloride hydrochloride in 200 mL CH2Cl2 dropwise, and stirred at room temperature for 15 h to give, after workup and silica gel chromatog., N'-[1-[4-[(4aR,10bR)-8,9-Dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-6-yl]phenyl]methanoyl]-N,N-diethylguanidine (II). 12 Compds. I including II showed -logIC50 (mol/L) of >8 against phosphodiesterase 4.

AN 2004:182846 CAPLUS
DN 140:235725
TI Preparation of 6-phenylphenanthridine derivatives as phosphodiesterase 4 (PDE4) inhibitors
IN Kley, Hans-Peter; Hatzelmann, Armin; Barsig, Johannes; Marx, Degenhard; Flockerzi, Dieter; Schmidt, Beate; Weinbrenner, Steffen
PA Altana Pharma A.-G., Germany
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004018431	A2	20040304	WO 2003-EP8967		20030813
	WO 2004018431	A3	20040422			
	W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, EE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW					
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR					
				EP 2002-18530	A	20020817
	CA 2495597	A1	20040304	CA 2003-2495597		20030813
				EP 2002-18530	A	20020817
				WO 2003-EP8967	W	20030813
	AU 2003253408	A1	20040311	AU 2003-253408		20030813
				EP 2002-18530	A	20020817
				WO 2003-EP8967	W	20030813
	EP 1537086	A2	20050608	EP 2003-792307		20030813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				EP 2002-18530	A	20020817
				WO 2003-EP8967	W	20030813
	JP 2005537312	T	20051208	JP 2004-530135		20030813
				EP 2002-18530	A	20020817
				WO 2003-EP8967	W	20030813
	US 2006116518	A1	20060601	US 2005-524634		20050216
				EP 2002-18530	A	20020817
				WO 2003-EP8967	W	20030813

OS MARPAT 140:235725
IT 667422-55-1P 667422-56-2P 667422-57-3P
667422-58-4P 667422-59-5P 667422-60-8P
667422-61-9P 667422-62-0P 667422-63-1P
667422-64-2P 667422-65-3P 667422-66-4P
667422-67-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylphenanthridine derivs. as phosphodiesterase 4 (PDE4) inhibitors for treating respiratory disorders and/or dermatoses dermatosis)

RN 667422-55-1 CAPLUS
CN Benzamide, N-[(diethylamino)iminomethyl]-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-56-2 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-1H-imidazol-2-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-57-3 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(imino-4-morpholinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-58-4 CAPLUS
CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-59-5 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[imino(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-60-8 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-61-9 CAPLUS
CN Benzamide, N-[amino(1H-benzimidazol-2-ylamino)methylene]-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-62-0 CAPLUS
CN Benzamide, N-[(3,4-dihydro-2(1H)-isoquinolinyl)iminomethyl]-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-63-1 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(imino-1-pyrrolidinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-64-2 CAPLUS
CN Benzamide, 4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[imino(phenylamino)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-65-3 CAPLUS
CN Benzamide, N-[(3,5-dimethyl-1H-pyrazol-1-yl)iminomethyl]-4-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-66-4 CAPLUS
CN Benzamide, N-[(diethylamino)iminomethyl]-3-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 667422-67-5 CAPLUS
CN Benzamide, 3-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(imino-4-morpholinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I

AB Title compds. [I; R = C6H4R6; R1,R2 = OH, (fluoro)alkoxy, cycloalkyl(meth)oxy; R1R2 = OCH2O or OCH2CH2O; R3,R4,R31 = H or alkyl; R3R31 = alkylene; R6 = CO2NR7R8 or CONR9R10; R7 = H, (cyclo)alkyl, (un)substituted Ph, etc.; R8 = (cyclo)alkyl, (un)substituted Ph, etc.; R9 = H or alkyl; R10 = (un)substituted pyridyl or -Ph; dashed line = optional addnl. bond] were prepared Thus, 3,4-(MeO)2C6H3CHO was condensed with MeNO2 and the nitrostyrene product cyclocondensed with CH2:CHCH:CH2 to give, in 4 addnl. steps, (-)-cis-2-(3,4-dimethoxyphenyl)cyclohexanamine which was N-acylated by 4-(MeO)C6H4NHCOC6H4(COCl)-3 to give (-)-cis-I [R = C6H4[CONHC6H4(OMe)-4]-3, R1 = R2 = OMe, R3 = R4 = R31 = H] as the N-oxide (II). Data for biol. activity of II were given.

AN 2000:493521 CAPLUS

DN 133:120241

TI Preparation of phenanthridine N-oxides as PDE-IV inhibitors

IN Flockerzi, Dieter; Amschler, Hermann; Hatzelmann, Armin; Bundschuh, Daniela; Beume, Rolf; Boss, Hildegard; Kley, Hans-Peter; Gutterer, Beate

PA Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Germany

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2000042017	A1	20000720	WO 2000-EP150		20000112
	W: AE, AL, AU, BA, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
				EP 1999-100707	A	19990115
	CA 2359404	A1	20000720	CA 2000-2359404		20000112
				EP 1999-100707	A	19990115
				WO 2000-EP150	W	20000112
	AU 2000021077	A	20000801	AU 2000-21077		20000112
				EP 1999-100707	A	19990115
				WO 2000-EP150	W	20000112
	EP 1147087	A1	20011024	EP 2000-901089		20000112
	EP 1147087	B1	20050511			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

			EP 1999-100707	A	19990115
			WO 2000-EP150	W	20000112
JP 2002534505	T	20021015	JP 2000-593585		20000112
			EP 1999-100707	A	19990115
			WO 2000-EP150	W	20000112
AT 295352	T	20050515	AT 2000-901089		20000112
			EP 1999-100707	A	19990115
			WO 2000-EP150	W	20000112
PT 1147087	T	20050930	PT 2000-901089		20000112
			EP 1999-100707	A	19990115
			WO 2000-EP150	W	20000112
ES 2242594	T3	20051116	ES 2000-901089		20000112
			EP 1999-100707	A	19990115
US 2002183350	A1	20021205	US 2001-889142		20010712
US 6538005	B2	20030325			
			EP 1999-100707	A	19990115
			WO 2000-EP150	W	20000112

OS MARPAT 133:120241

IT 284465-36-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenanthridine N-oxides as PDE-IV inhibitors)

RN 284465-36-7 CAPLUS

CN Benzamide, 3-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-5-oxido-6-phenanthridinyl]-N-(4-methoxyphenyl)-, rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 284465-37-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenanthridine N-oxides as PDE-IV inhibitors)

RN 284465-37-8 CAPLUS

CN Benzamide, 3-[(4aR,10bR)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-(4-methoxyphenyl)-, rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I

AB Title compds. [I; R = ZSO2NR'R8 or ZCONR9R10; R1,R2 = OH, (fluoro)alkoxy, cycloalkyl(meth)oxy; R1R2 = alkylenedioxy; R3,R4,R7 = H or alkyl; R5,R6 = H; R5R6 = bond; R',R8 = H, alkyl, cycloalkyl(methyl), (un)substituted Ph; R9 = H or alkyl; R10 = (un)substituted Ph or -pyridyl; Z = phenylene] were prepared Thus, cis-2-(3-ethoxy-4-methoxyphenyl)cyclohexylamine (preparation given) was amidated by 4-(H2NO2S)C6H4COCl to give, after cyclization, I [R = C6H4(SO2NH2)-4, R1 = OMe, R2 = OEt, R3-R7 = H]. Data for biol. activity of the prepared I were given.

AN 1999:96219 CAPLUS

DN 130:153582

TI Preparation of hexahydrophenanthridine-6-ylbenzenesulfonamides and analogs as phosphodiesterase 4 inhibitors

IN Amschler, Hermann; Flockerzi, Dieter; Ulrich, Wolf-Rudiger; Bar, Thomas; Martin, Thomas; Schudt, Christian; Hatzelmann, Armin; Beume, Rolf; Hafner, Dietrich; Boss, Hildegard; Kley, Hans-peter; Gutterer, Beate

PA Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Germany

SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9905113	A1	19990204	WO 1998-EP4478	19980718
	W: AL, AU, BA, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				EP 1997-112793 A	19970725
	CA 2297911	A1	19990204	CA 1998-2297911	19980718
	CA 2297911	C	20070904		
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	AU 9891546	A	19990216	AU 1998-91546	19980718
	AU 756349	B2	20030109		
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	EP 1000035	A1	20000517	EP 1998-943742	19980718
	EP 1000035	B1	20021127		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	EE 200000032	A	20001016	EE 2000-32	19980718
	EE 4189	B1	20031215		
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	HU 2000003311	A2	20010328	HU 2000-3311	19980718
	HU 2000003311	A3	20021028		
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	JP 2001510827	T	20010807	JP 2000-504112	19980718
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	AT 228507	T	20021215	AT 1998-943742	19980718
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	PT 1000035	T	20030430	PT 1998-943742	19980718
				EP 1997-112793 A	19970725
	ES 2189235	T3	20030701	ES 1998-943742	19980718
				EP 1997-112793 A	19970725
	IL 133825	A	20051218	IL 1998-133825	19980718
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	CZ 296064	B6	20060111	CZ 2000-281	19980718
				EP 1997-112793 A	19970725
	PL 191094	B1	20060331	PL 1998-338452	19980718
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718
	US 6121279	A	20000919	US 2000-462508	20000124
				EP 1997-112793 A	19970725
				WO 1998-EP4478 W	19980718

OS MARPAT 130:153582

IT 220167-05-5P 220167-09-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hexahydrophenanthridine-6-ylbenzenesulfonamides and analogs as phosphodiesterase 4 inhibitors)

RN 220167-05-5 CAPLUS

CN Benzamide, 4-[(4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-3-pyridinyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 220167-09-9 CAPLUS
CN Benzamide, N-(4-cyanophenyl)-4-[(4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I

AB Title compds. [I; R1, R2 = OH, alkoxy, cycloalkoxy, cycloalkylmethoxy, fluoroalkoxy; R1R2 = alkylenedioxy; R3, R31 = H, alkyl; R3R31 = alkylene; R4 = H, alkyl; R5, R51 = H; R5R51 = bond; R6 = (modified) carboxyphenyl], were prepared for treatment of airway diseases. Thus, cis-N-[2-(3,4-dimethoxyphenyl)cyclohexyl]-4-methoxycarbonylbenzamide (preparation given) was stirred 8 h at 50° with POCl3 in MeCN to give 38.6% cis-8,9-dimethoxy-6-[4-(methoxycarbonyl)phenyl]-1,2,3,4,4a,10b-hexahydrophenanthridine. The latter inhibited phosphodiesterase IV with -log IC50 = 7.39.

AN 1997:533622 CAPLUS

DN 127:205483

TI Preparation of carboxyphenylhexahydrophenanthridines as phosphodiesterase IV inhibitors.

IN Amschler, Hermann; Flockerzi, Dieter; Ulrich, Wolf-Rudiger; Bar, Thomas; Martin, Thomas; Schudt, Christian; Hatzelmann, Armin; Beume, Rolf; Hafner, Dietrich; Boss, Hildegard; Kley, Hans-Peter; Goebel, Karl-Josef; Gutterer, Beate

PA BYK Gulden Lomberg Chemische Fabrik G.m.b.H., Germany; Gutterer, Beate

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9728131	A1	19970807	WO 1997-EP402	19970130
	W: AL, AU, BA, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1996-19603321 A	19960131
				EP 1996-101791 A	19960208
	DE 19603321	A1	19970807	DE 1996-19603321	19960131
	CA 2245142	A1	19970807	CA 1997-2245142	19970130
	CA 2245142	C	20041130		
				DE 1996-19603321 A	19960131
				EP 1996-101791 A	19960208
				WO 1997-EP402 W	19970130
	AU 9717199	A	19970822	AU 1997-17199	19970130
	AU 707058	B2	19990701		
				DE 1996-19603321 A	19960131
				EP 1996-101791 A	19960208
				WO 1997-EP402 W	19970130
	EP 882021	A1	19981209	EP 1997-904354	19970130
	EP 882021	B1	20030305		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
CN 1214681	A	19990421	CN 1997-193458	19970130
			DE 1996-19603321	A 19960131
HU 9900666	A2	19990628	HU 1999-666	19970130
HU 221380	B1	20020928		
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
BR 9707233	A	19990720	BR 1997-7233	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
NZ 331374	A	20000128	NZ 1997-331374	19970130
			DE 1996-19603321	A 19960131
			WO 1997-EP402	W 19970130
JP 2000503996	T	20000404	JP 1997-527140	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
SK 282084	B6	20011008	SK 1998-1024	19970130
			DE 1996-19603321	A 19960131
			WO 1997-EP402	W 19970130
EE 3523	B1	20011015	EE 1998-223	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
CZ 289340	B6	20020116	CZ 1998-2414	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
IL 125286	A	20020814	IL 1997-125286	19970130
			DE 1996-19603321	A 19960131
			WO 1997-EP402	W 19970130
AT 233735	T	20030315	AT 1997-904354	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130
PT 882021	T	20030731	PT 1997-904354	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
ES 2194180	T3	20031116	ES 1997-904354	19970130
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
PL 187127	B1	20040531	PL 1997-328019	19970130
			DE 1996-19603321	A 19960131
			WO 1997-EP402	W 19970130
NO 9803505	A	19980911	NO 1998-3505	19980730
NO 311214	B1	20011029		
			DE 1996-19603321	A 19960131
			WO 1997-EP402	W 19970130
US 6191138	B1	20010220	US 1998-117507	19980731
			DE 1996-19603321	A 19960131
			EP 1996-101791	A 19960208
			WO 1997-EP402	W 19970130

OS CASREACT 127:205483; MARPAT 127:205483
IT 194735-32-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxyphenylhexahydrophenanthridines as phosphodiesterase IV inhibitors)

RN 194735-32-5 CAPLUS

CN Benzamide, 4-(1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl)-N-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.